news
microRNA-146a controls age-related bone loss
We want to draw your attention to the latest publication in cooperation with TAmiRNA. The study identifies a novel and unexpected role of miR‐146a in bone homeostasis. miR‐146a increases with age and acts as an epigenetic molecular switch terminating bone accrual, leading to bone loss during aging by downregulating bone anabolic Wnt signaling. Conversely, loss of miR‐146a leads to continuous bone accrual during [...]
MedUni Wien “Researcher of the Month” Oktober 2020
We want to congratulate Dr. Patrick Starlinger to his award “Researcher of the Month” for his work in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Click here for more information on TAmiRNA services Click here to read the story
Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize
The “Houska“ Prize, awarded annually by the B&C Foundation, is Austria´s biggest private award for applied research. Dr. Michael Nodine, Gregor Mendel Institute of Molecular Plant Biology (GMI), was nominated for his work on the development of methods for nucleic acid quantification. A major issue they encountered was the lack of absolute quantification of small RNA levels, making the comparison between tissues difficult. To [...]
microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy MonitoringmicroRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring
biomarker, biomarkers, microRNA, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR
microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring
We want to draw your attention to the latest review of TAmiRNA and the King's College London, in Cardiovascular Diabetology. "microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring." Krammer TL, Mayr M & Hackl M. Int. J. Mol. Sci. 2020, 21(10), 3477; doi.org/10.3390/ijms21103477 In this review, we explain the secretion of miRNAs upon platelet activation and discuss the potential use [...]
TAmiRNAs SARS CoV-2 offers
TAmiRNA now offers a test service for direct detection of SARS-CoV-2 viral RNA in biological samples. Moreover we offer a validated SARS-CoV-2 Antibody Test (Lateral Flow Method). Click here for more Information
TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA
The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will deliver a presentation on ‘Next-generation sequencing pipeline for genome-scale analysis of circulating microRNAs as discovery approach for safety biomarkers’ (P338) during the Biomarkers Poster Session on Day Two, CC Exhibit Hall, of the meeting. [...]
New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment responseNew evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response
biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus
New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response
We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response in type-2 diabetics with cardiovascular disease. "Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels." Parker WAE, Schulte C, Bawari T, et al. Cardiovasc Diabetol. 2020 Jan 7;19(1):3. doi: 10.1186/s12933-019-0981-3. click here to [...]
meet TAmiRNA 2020
2020 TAmiRNA showcases at several conferences - take advantage, meet the TAmiRNA experts and discuss our latest developments and your needs! 2nd Longevity Therapeutics conference, 28-30 January 2020, San Francisco, California, USA SOT 59th Annual Meeting and ToxExpo, 15-19 March 2020, Anaheim, California, USA - cancelled Osteologie 2020, 5-6 September 2020, virtual meeting 47th annual meeting of the European Calcified Tissue Society, 22-24 [...]
MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.
biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine
MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.
We want to draw your attention to the latest publication of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in AUVA Research Center, in cooperation with TAmiRNA GmbH, in Bone. "MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis." Kocijan R, Weigl M, Skalicky S, et al. Bone 2019 Volume 131, February [...]